SynthesisAesthetic plastic surgery2026
Effectiveness of Radiofrequency Microneedling in the Treatment of Dermatological Conditions: A Systematic Review.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Effects and Safety of Radiofrequency Microneedling for the Management of Melasma: A Retrospective Study.Aesthetic surgery journal. Open forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiofrequency microneedling (RFMN) utilizes RF energy delivered via needles to the dermis to enhance texture, reduce laxity, and improve dyschromia. However, evidence has been fragmented by indication/device heterogeneity. We evaluated clinical effectiveness, safety, and patient-reported outcomes (PROs) of RFMN across dermatological conditions.
methodsSearches of PubMed, Google Scholar, and Semantic Scholar (January 2015-July 2025) (PROSPERO registration: CRD420251089393) were conducted, and English-language RCTs, cohort studies, case series, and reports of RFMN across skin indications were included (non-human studies excluded). A modified Critical Appraisal Skills Programme (CASP) checklist was used for quality analysis. Findings were narratively synthesized.
resultsForty-one studies met the criteria (15 RCTs, 19 prospective non-randomized studies, 5 prospective cohorts, 2 case series) spanning diverse geographies and Fitzpatrick skin types. For atrophic acne scars, RFMN consistently reduced scar scores and demonstrated efficacy comparable to fractional lasers. For skin laxity/photoaging, RFMN improved wrinkle scales, dermal density, and submental volume, (histologically evidenced). Additional benefits were noted for rosacea, melasma, and striae, though effect sizes varied. In primary axillary hyperhidrosis, botulinum toxin A outperformed RFMN for symptom reduction/comfort. Safety was favorable; erythema, edema, and transient pain predominated; post-inflammatory hyperpigmentation was infrequent and self-limited. PROs indicated high satisfaction and minimal downtime. Reporting of technical parameters, especially temperature, pulse width, and cooling, was inconsistent.
conclusionsRFMN is safe, well-tolerated, with credible efficacy across multiple indications and skin types, and an attractive recovery profile. Standardized outcomes, longer follow-up periods, and rigorous reporting of device settings are necessary to refine protocols and facilitate head-to-head device comparisons. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.